HopeStage
Back to all studies
CompletedNCT02075528

Early Response to Paliperidone for Schizophrenia

About this titleRead the official source — NCT02075528
Medication studyAges 18–65Taiwan
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
TaipeiSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2009
Recruitment status
Completed
Enrollment listed in the registry
41
Sponsor
Taipei City Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Taiwan
Age range
From 18 Years to 65 Years
Official registry ID
NCT02075528
Official title
Show the full official title

Early Prediction of Clinical Response, Metabolic Change, and Pharmacokinetics in Taiwanese Patients With Schizophrenia Patients Treated by Paliperidone ER: an Open-Label Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Taipei

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Taipei City Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies